- Home
- CLGN vs RDI Comparison
CLGN vs RDI Comparison
Compare CLGN & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- RDI
- Stock Information
- Founded
- CLGN 2004
- RDI 1937
- Country
- CLGN Israel
- RDI United States
- Employees
- CLGN N/A
- RDI N/A
- Industry
- CLGN Industrial Specialties
- RDI Movies/Entertainment
- Sector
- CLGN Health Care
- RDI Consumer Discretionary
- Exchange
- CLGN Nasdaq
- RDI Nasdaq
- Market Cap
- CLGN 37.4M
- RDI 30.1M
- IPO Year
- CLGN N/A
- RDI N/A
- Fundamental
- Price
- CLGN $1.82
- RDI $1.33
- Analyst Decision
- CLGN Strong Buy
- RDI Hold
- Analyst Count
- CLGN 2
- RDI 1
- Target Price
- CLGN $12.50
- RDI $2.40
- AVG Volume (30 Days)
- CLGN 12.7K
- RDI 36.3K
- Earning Date
- CLGN 05-28-2025
- RDI 05-19-2025
- Dividend Yield
- CLGN N/A
- RDI N/A
- EPS Growth
- CLGN N/A
- RDI N/A
- EPS
- CLGN N/A
- RDI N/A
- Revenue
- CLGN $515,000.00
- RDI $210,527,000.00
- Revenue This Year
- CLGN $2,177.67
- RDI $9.74
- Revenue Next Year
- CLGN $56.52
- RDI $6.39
- P/E Ratio
- CLGN N/A
- RDI N/A
- Revenue Growth
- CLGN N/A
- RDI N/A
- 52 Week Low
- CLGN $1.82
- RDI $1.17
- 52 Week High
- CLGN $6.75
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- CLGN 23.18
- RDI 52.82
- Support Level
- CLGN $2.00
- RDI $1.23
- Resistance Level
- CLGN $2.40
- RDI $1.30
- Average True Range (ATR)
- CLGN 0.21
- RDI 0.07
- MACD
- CLGN -0.01
- RDI 0.01
- Stochastic Oscillator
- CLGN 3.59
- RDI 50.00
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.